Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Ochrana před dezinformacemi o vakcínách proti HIV u dospívajících dívek a mladých žen v Jižní Africe (PROTECT)

28. srpna 2026 aktualizováno: University of Pennsylvania

Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.

Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

2163

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Johannesburg, Jižní Afrika
        • Health Economics and Epidemiology Research Office, University of the Witwatersrand

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 29 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Female
  • Age 18-29 years
  • Self-reported history of sexual activity in the past 12 months
  • Self-reported HIV-negative status or unknown HIV status at enrolment
  • Willing and able to provide written informed consent
  • Able to read and understand English

Exclusion Criteria:

  • Unwilling or unable to provide consent for study participation.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Control

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Jiný: Enhanced inoculation message

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
HIV Vaccine Intention, at the End of the Baseline Assessment
Časové okno: At the end of the baseline assessment

Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

At the end of the baseline assessment

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
HIV Vaccine Intention, Follow-up
Časové okno: 2-4 weeks

Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

2-4 weeks
Recommend to Friends, at the End of the Baseline Assessment
Časové okno: At the end of the baseline assessment

Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

At the end of the baseline assessment
Recommend to Friends, Follow-up
Časové okno: 2-4 weeks

Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

2-4 weeks
Credibility of Inoculated Exposure #1
Časové okno: At the end of the baseline assessment

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #2
Časové okno: At the end of the baseline assessment

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #3
Časové okno: At the end of the baseline assessment

Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #4
Časové okno: At the end of the baseline assessment

Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #5
Časové okno: At the end of the baseline assessment

Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #6
Časové okno: At the end of the baseline assessment

Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #1
Časové okno: At the end of the baseline assessment

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #2
Časové okno: At the end of the baseline assessment

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #3
Časové okno: At the end of the baseline assessment

Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #4
Časové okno: At the end of the baseline assessment

Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #5
Časové okno: At the end of the baseline assessment

Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #6
Časové okno: At the end of the baseline assessment

Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #1
Časové okno: At the end of the baseline assessment

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #7
Časové okno: At the end of the baseline assessment

Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #3
Časové okno: At the end of the baseline assessment

Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #4
Časové okno: At the end of the baseline assessment

Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #5
Časové okno: At the end of the baseline assessment

Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #6
Časové okno: At the end of the baseline assessment

Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #1, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of Inoculated Exposure #2, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Shareability of Inoculated Exposure #1, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of Inoculated Exposure #2, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Anxiousness of Inoculated Exposure #1, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of Inoculated Exposure #2, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Credibility of New Claims, Exposure #12, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #8, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #9, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #10, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #11, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness o of New Claims, Exposure #12, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Claim #8, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #9, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #10, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #11, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #12, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #8, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #9, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #10, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #11, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Credibility of Inoculated Exposure #7
Časové okno: At the end of the baseline assessment

Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #7
Časové okno: At the end of the baseline assessment

Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #2
Časové okno: At the end of the baseline assessment

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of New Claims, Exposure #13, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness of New Claims, Exposure #13, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #13, Follow-up
Časové okno: 2-4 weeks

Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

24. července 2025

Primární dokončení (Aktuální)

16. října 2025

Dokončení studie (Odhadovaný)

1. června 2027

Termíny zápisu do studia

První předloženo

7. listopadu 2024

První předloženo, které splnilo kritéria kontroly kvality

18. listopadu 2024

První zveřejněno (Aktuální)

22. listopadu 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

24. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

28. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 1R01MH132401 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Popis plánu IPD

The investigators are still determining the data sharing plan and if we will be sharing IPD yet

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .